Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Columbia University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07471139CT.gov SWITCH: Apixaban vs Vitamin K in HM3 | — | Not Yet Recruiting | — | — | — |
NCT07237308CT.gov BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis | — | Not Yet Recruiting | — | — | — |
NCT06486792CT.gov Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation | — | Recruiting | — | — | — |
NCT05679024CT.gov Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation | — | Recruiting | — | — | — |
NCT05643573CT.gov A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke | — | Terminated | — | — | — |
NCT04878497CT.gov Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty | — | Unknown | — | — | — |
NCT04808934CT.gov NOAC Portuguese Real World Study | — | Withdrawn | — | — | — |
NCT04045665CT.gov Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | — | Recruiting | — | — | — |
NCT03192215CT.gov AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke | — | Terminated | — | — | — |
NCT03119116CT.gov Use of Direct Oral Anticoagulants in UK | — | Completed | — | — | — |
Show 3 more trialsShow fewer
NCT02889562CT.gov Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation | — | Completed | — | — | — |
NCT01938248CT.gov Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation | — | Completed | — | — | — |
NCT02283294CT.gov Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apixaban (this asset) | Columbia University | Approved | BB · 65 |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Aspirin | China National Center for Cardiovascular Diseases | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Apixaban
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Venous Thromboembolism | — | P4 | BBB · 79 |
| Atrial Fibrillation | — | P4 | BBB · 77 |
| Transient Ischemic Attack | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apixaban in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apixaban-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →